Valneva, a specialty vaccine company and member of Atlanpole Biotherapies, announced that the European Commission (“EC”) has approved an agreement... View Article
Author Archives for Adeline Chauvigné
Valneva wins approval from European Commission to supply Covid-19 vaccines
10 May 2025Valneva, a specialty vaccine company and member of Atlanpole Biotherapies, announced that the European Commission (“EC”) has approved an agreement... View Article
New member | AGS-M
AGS-M is a young CDMO dedicated to the development, the optimization and validation of manufacturing processes (production, clarification, purification and... View Article
New member | AGS-M
10 May 2025AGS-M is a young CDMO dedicated to the development, the optimization and validation of manufacturing processes (production, clarification, purification and... View Article
Valneva raises €88 million
Valneva, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new... View Article
Valneva raises €88 million
10 May 2025Valneva, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new... View Article
Innovative medical device same™ by i-SEP : promising clinical results
MedTech – Autotransfusion or IntraOperative Cell Recovery Recovery of platelets in addition to red blood cells, a world premiere Following... View Article
Innovative medical device same™ by i-SEP : promising clinical results
10 May 2025MedTech – Autotransfusion or IntraOperative Cell Recovery Recovery of platelets in addition to red blood cells, a world premiere Following... View Article
KetoM+ is launching Cétoprane, a ketogenic medical food (DADFMS)
KetoM+, member of our network based in Le Mans, is launching Cétoprane, a ketogenic medical food (DADFMS) nutritionally adapted for... View Article
KetoM+ is launching Cétoprane, a ketogenic medical food (DADFMS)
10 May 2025KetoM+, member of our network based in Le Mans, is launching Cétoprane, a ketogenic medical food (DADFMS) nutritionally adapted for... View Article
New member | Elisabeth Richard Business Development Consulting
Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article
New member | Elisabeth Richard Business Development Consulting
10 May 2025Elisabeth Richard BD Consulting offers a business development (France and International) expertise in the fields of health and innovation having... View Article
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
10 May 2025VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S) Neutralizing... View Article
Owkin joins OPTIMA: new research project to improve the treatment of prostate, breast and lung cancer patients using AI
Owkin is delighted to be part of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence),... View Article
Owkin joins OPTIMA: new research project to improve the treatment of prostate, breast and lung cancer patients using AI
10 May 2025Owkin is delighted to be part of OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence),... View Article
Hawkcell & Cynbiose team up in a strategic partnership
Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and... View Article
Hawkcell & Cynbiose team up in a strategic partnership
10 May 2025Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and... View Article
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
Further Strengthens Global Intellectual Property Portfolio for Tedopi® until 2038 OSE Immunotherapeutics announced today that it has received notice of... View Article
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
10 May 2025Further Strengthens Global Intellectual Property Portfolio for Tedopi® until 2038 OSE Immunotherapeutics announced today that it has received notice of... View Article